ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
Dow Jones
39.387,76
0,85%
Euro vs US Dollar
1,07766
-0,05%
Bitcoin
62.748,90
-0,48%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Allergy Therapeutics Plc (AGY)

  7. Allergy Therapeutics Plc (AGY) News

AGY

Allergy Therapeutics (AGY)

Allergy Therapeutics Plc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:AGY
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202421h22Alliance NewsAlliance NewsTRADING UPDATES: Abingdon Health buys IVDeology HoldingsLSE:AGYAllergy Therapeutics Plc
07/05/202408h00RNS Regulatory NewsAllergy Therapeutics PLC Further detail from G306 Phase III field trialLSE:AGYAllergy Therapeutics Plc
03/04/202408h00RNS Regulatory NewsAllergy Therapeutics PLC Director ResignationLSE:AGYAllergy Therapeutics Plc
27/03/202417h13Alliance NewsAlliance NewsEARNINGS AND TRADING: Solid State ups outlook; Quartix trading in lineLSE:AGYAllergy Therapeutics Plc
27/03/202408h00RNS Regulatory NewsAllergy Therapeutics PLC Interim Results for six months ended 31 Dec 2023LSE:AGYAllergy Therapeutics Plc
27/03/202408h00RNS Regulatory NewsAllergy Therapeutics PLC Update on fundingLSE:AGYAllergy Therapeutics Plc
12/03/202415h06Alliance NewsAlliance NewsAllergy Therapeutics starts dosing patients in peanut allergy trialLSE:AGYAllergy Therapeutics Plc
12/03/202409h59RNS Regulatory NewsAllergy Therapeutics PLC VLP Peanut PROTECT Trial UpdateLSE:AGYAllergy Therapeutics Plc
12/03/202408h00RNS Non-RegulatoryAllergy Therapeutics PLC VLP Peanut PROTECT Trial UpdateLSE:AGYAllergy Therapeutics Plc
11/03/202408h00RNS Regulatory NewsAllergy Therapeutics PLC Appointment of Shaun Furlong to Board of DirectorsLSE:AGYAllergy Therapeutics Plc
08/03/202414h49RNS Regulatory NewsAllergy Therapeutics PLC Result of AGMLSE:AGYAllergy Therapeutics Plc
14/02/202411h22Alliance NewsAlliance NewsAllergy Therapeutics forecasts revenue drop but trials going wellLSE:AGYAllergy Therapeutics Plc
14/02/202408h00RNS Regulatory NewsAllergy Therapeutics PLC Half-Year Trading Update 2024LSE:AGYAllergy Therapeutics Plc
09/02/202416h07RNS Regulatory NewsAllergy Therapeutics PLC Notice of 2023 Annual General MeetingLSE:AGYAllergy Therapeutics Plc
30/01/202411h38Alliance NewsAlliance NewsAllergy Therapeutics resumes trading on AIM; annual revenue plungesLSE:AGYAllergy Therapeutics Plc
30/01/202408h30RNS Regulatory NewsAIM Restoration - Allergy Therapeutics plcLSE:AGYAllergy Therapeutics Plc
30/01/202408h00RNS Regulatory NewsAllergy Therapeutics PLC Publication of Annual Report and Accounts 2023LSE:AGYAllergy Therapeutics Plc
04/01/202413h29UK RegulatoryAllergy Therapeutics PLC Total Voting RightsLSE:AGYAllergy Therapeutics Plc
02/01/202408h30UK RegulatoryAIM Suspension - Allergy Therapeutics plcLSE:AGYAllergy Therapeutics Plc
27/12/202315h17Alliance NewsAlliance NewsIN BRIEF: Allergy Therapeutics amends facility, plans warrant issueLSE:AGYAllergy Therapeutics Plc
27/12/202313h01UK RegulatoryAllergy Therapeutics PLC Amendment to existing Facility AgreementLSE:AGYAllergy Therapeutics Plc
15/12/202322h09Alliance NewsAlliance NewsEARNINGS AND TRADING: Redx full year revenue tumbles; loss widensLSE:AGYAllergy Therapeutics Plc
15/12/202313h48UK RegulatoryAllergy Therapeutics PLC Annual Report and Accounts DelayedLSE:AGYAllergy Therapeutics Plc
13/12/202317h54UK RegulatoryAllergy Therapeutics PLC PDMR dealing and Total Voting RightsLSE:AGYAllergy Therapeutics Plc
13/12/202311h11Alliance NewsAlliance NewsAllergy Therapeutics shares jump as hails grass allergy jab dataLSE:AGYAllergy Therapeutics Plc
13/12/202308h00UK RegulatoryAllergy Therapeutics PLC G306 Phase III trial meets key endpointsLSE:AGYAllergy Therapeutics Plc
11/12/202311h40Alliance NewsAlliance NewsIN BRIEF: Allergy Therapeutics stock falls on lower sales outlookLSE:AGYAllergy Therapeutics Plc
11/12/202308h00UK RegulatoryAllergy Therapeutics PLC Update on fundingLSE:AGYAllergy Therapeutics Plc
01/12/202308h00UK RegulatoryAllergy Therapeutics PLC Total Voting RightsLSE:AGYAllergy Therapeutics Plc
28/11/202316h03UK RegulatoryAllergy Therapeutics PLC Holding(s) in CompanyLSE:AGYAllergy Therapeutics Plc
 Showing the most relevant articles for your search:LSE:AGY

Kürzlich von Ihnen besucht

AMEX
SPY
SPDR S&P 500
USOTC
RHHBY
Roche (QX)
NYSE
KO
Coca Cola
NYSE
XOM
Exxon Mobil
FX
EURUSD
Euro vs US Dollar
NASDAQ
QQQ
Invesco QQQ Trust Series 1
CCOM
SILVER
SILVER
TG
BAS
BASF
TG
BAYN
Bayer
CCOM
US30
US 30
TG
DBK
Deutsche Bank
NASDAQ
MSFT
Microsoft
NASDAQ
AAPL
Apple
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten